Payment overview · 2025
General Payments
$36,107.15
70 reported records · 11 companies
Healthcare provider profile · identity verified
Vikram Arora, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BIRMINGHAM, AL · NPI 1255335246
Verified facts
What the public records show
CMS Open Payments records show Vikram Arora, MD received $36,107.15 in general payments during 2025 across 70 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance, Uptravi.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Uptravi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 460 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 460 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 677 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14,025.02 | 38.8% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13,802.64 | 38.2% | 24 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $7,800.00 | 21.6% | 7 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $154.95 | 0.4% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $124.84 | 0.3% | 15 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $64.22 | 0.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.80 | 0.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.53 | 0.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.80 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.70 | 0.0% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $13.65 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,115.00 | 20 |
| Travel and Lodging | $2,857.50 | 3 |
| Food and Beverage | $1,121.00 | 46 |
| Entertainment | $13.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $21,602.64 | 31 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14,025.02 | 11 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $124.84 | 15 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $121.98 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $64.22 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.53 | 2 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $32.97 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 677 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 298 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 460 | exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
108 | 15 |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
460 | 101 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
460 | 101 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
298 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
677 | 120 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 885 | 255 |
| Atorvastatin Calcium | Atorvastatin Calcium | 764 | 241 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 729 | 216 |
| Eliquis | Apixaban | 677 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 528 | 167 |
| Spironolactone | Spironolactone | 514 | 173 |
| Jardiance | Empagliflozin | 460 | 101 |
| Losartan Potassium | Losartan Potassium | 416 | 128 |
| Carvedilol | Carvedilol | 391 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 103 |
| Entresto | Sacubitril/Valsartan | 298 | 60 |
| Lisinopril | Lisinopril | 278 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 61 |
| Furosemide | Furosemide | 197 | 71 |
| Xarelto | Rivaroxaban | 188 | 42 |
| Allopurinol | Allopurinol | 186 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 45 |
| Metformin Hcl Er | Metformin Hcl | 141 | 46 |
| Ozempic | Semaglutide | 126 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 125 | 38 |
| Metformin Hcl | Metformin Hcl | 118 | 43 |
| Opsumit | Macitentan | 108 | 15 |
| Fenofibrate | Fenofibrate | 103 | 32 |
| Atenolol | Atenolol | 98 | 30 |
| Repatha Sureclick | Evolocumab | 97 | 23 |
| Potassium Chloride | Potassium Chloride | 96 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 26 |
| Farxiga | Dapagliflozin Propanediol | 86 | 19 |
| Flecainide Acetate | Flecainide Acetate | 75 | 24 |
| Icosapent Ethyl | Icosapent Ethyl | 75 | 22 |
| Simvastatin | Simvastatin | 75 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 69 | 20 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Ramipril | Ramipril | 64 | 29 |
| Multaq | Dronedarone Hcl | 60 | suppressed |
| Vascepa | Icosapent Ethyl | 57 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 15 |
| Midodrine Hcl | Midodrine Hcl | 54 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 17 |
| Ranolazine Er | Ranolazine | 49 | 17 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 17 |
| Nitroglycerin | Nitroglycerin | 40 | 27 |
| Sildenafil Citrate | Sildenafil Citrate | 40 | 13 |
| Irbesartan | Irbesartan | 39 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 12 |
| Lorazepam | Lorazepam | 35 | 21 |
| Valsartan | Valsartan | 35 | 13 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Eplerenone | Eplerenone | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Uptravi | Selexipag | 17 | suppressed |
| Tyvaso Dpi | Treprostinil | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Orenitram Er | Treprostinil Diolamine | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36,107.15 · 70 records | Bayer Healthcare Pharmaceuticals Inc. | CARDIOMEMS, ELIQUIS, ENTRESTO, JARDIANCE, Kerendia, LINQ II, LifeVest, NFC-700, NURTEC ODT, OCT OPHTHALMOSCOPE, OPSYNVI, PANORAMIC OPHTHALMOSCOPE, PASCAL, SAPIEN 3 Ultra RESILIA, TRICLIP, UPTRAVI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error